Home / Eight IP picks up Colonial small-cap mandate

Eight IP picks up Colonial small-cap mandate

Kerry Series 
Eight Investment Partners (8IP) has doubled the size of its Australian small-cap funds with the confirmation last week of a $55 million mandate from Colonial First State – the firm’s first institutional investor.
8IP was established in 2009 by Kerry Series, a co-founder of Perennial Investment Partners and former head of Asia Pacific equities at AMP Capital. He and other staff bought out the majority shareholder in the firm, South Africa’s Sanlam, in March last year. Sanlam had earlier purchased small-cap manager Atom Funds Management, with 8IP rebranding that fund in 2012.
Series said last week the Colonial mandate represented a milestone for the firm, which had until recently attracted mainly high-net-worth investors.
The mandate will be co-managed by Series and another principal, Stephen Walsh.
8IP aims to identify three types of companies in its research: ‘stars’, ‘turnarounds’ and under-researched stocks, Series said. The three-year average return for the small-cap strategy is 17.4 per cent net of fees.

Investor Strategy News




  • Print Article

    Related
    ‘Bubble thinking’: Howard Marks on market blow-ups

    Higher starting valuations usually lead to lower returns, but the most important part of a bubble is “highly skewed psychology” – and investors remain anchored to sanity.

    David Chaplin | 10th Jan 2025 | More
    ‘Martian real estate’ and bittersweet farewells: ISN’s top 10 stories of 2024

    This year’s top 10 stories included a peek into AustralianSuper’s international equities build out in London, AMP’s move to slash employee benefits, and plenty of hard-hitting analysis of the issues that matter in institutional investment. But the real story is how readers helped shape all of that coverage.

    Lachlan Maddock | 18th Dec 2024 | More
    ‘Nothing will stop me’: Stuart Place rides 15,451 km for son’s rare disease

    Orbis’ Stuart Place is riding from Melbourne to the Moon and Back to fund a treatment for the “monster of a disease” that his youngest son was born with. The investment industry is rallying behind him.

    Lachlan Maddock | 18th Dec 2024 | More
    Popular